Abstract: A pre-filled syringe for injecting a drug composition into an eye comprises: a syringe barrel (1) comprising a proximal end and a distal end; a floating seal (3) in the syringe barrel (1); a needle base proximal to the floating seal (3), wherein the floating seal (3) and the needle base elastically engage each other; a drug composition, wherein the drug composition is contained in a lumen (7) formed by the floating seal (3) and the distal end of the syringe barrel (1); a needle (6) for insertion into the eye, the needle (6) comprising: (i) a needle proximal end engaging the needle base; (ii) a needle distal end; (iii) a needle distal opening (6a); (iv) a needle body opening (6b) between the needle proximal end and the needle distal end, wherein the needle body opening (6b) is proximal to the needle distal opening (6a); and (v) a needle body passageway connecting the needle distal opening (6a) and the needle body opening (6b), wherein the needle base is configured to advance the needle (6) distally toward and/

Abstract: It relates to methods and compositions for determining anatomical response to an VEGF antagonist treatment in a subject's eye, comprising determining a VEGF level in the aqueous humor of the subject or in combination with determining a bl-CMT level in the subject, wherein a determined VEGF level higher than a VEGF cut-off value/range or in combination with a determined bl-CMT level higher than a bl-CMT cut off value/range indicate that the eye has a good anatomical response to intravitreal, suprachoroidal, and/or subretinal VEGF antagonist treatment, wherein a determined VEGF level lower than the VEGF cut-off value/range, or a determined bl-CMT level lower than the bl-CMT cut off value/range indicates that the eye has a poor anatomical response to intravitreal, suprachoroidal, and/or subretinal VEGF antagonist treatment. The aqueous humor VEGF level and/or the bl-CMT level can be used as a companion diagnostic to predict responsiveness of the subject to anti-VEGF therapies.

Abstract: A triamcinolone acetonide pharmaceutical composition and a preparation method therefor. The pharmaceutical composition contains the following ingredients: (i) a triamcinolone acetonide active ingredient, (ii) hyaluronic acid or a salt thereof. (iii) a buffering agent; and (iv) a tonicity adjustment agent. The pharmaceutical composition has a suitable viscosity, osmotic pressure and particle size range and is easily injected, especially administrated by means of a suprachoroidal space injection.

Abstract: A medical puncturing device and a system. The medical puncturing device includes a syringe barrel (1), a gasket seal (3), a push shaft (2), an elastic element (12) and a catheter (16). The medical puncturing device enables injection, access, expansion, and/or device implantation in an apparent or potential tissue void, cavity, or vessel (e.g., an epidural space), and is especially useful for achieving precise control of puncturing depth and needle placement, as well as steady injection and injection of a defined volume (e.g., for epidural anesthesia).

Abstract: Disclosed is a method for preparing a tear diluent, and provided are a tear sample eluent and a tear sample collection and treating apparatus. A small-volume tear sample can be stably collected using an absorbent material, and a substance to be tested of the sample can be stably released after elution using the sample eluent provided in the present disclosure.

Abstract: It relates to methods and compositions for determining anatomical response to an VEGF antagonist treatment in a subject's eye, comprising determining a VEGF level in the aqueous humor of the subject or in combination with determining a bl-CMT level in the subject, wherein a determined VEGF level higher than a VEGF cut-off value/range or in combination with a determined bl-CMT level higher than a bl-CMT cut off value/range indicate that the eye has a good anatomical response to intravitreal, suprachoroidal, and/or subretinal VEGF antagonist treatment, wherein a determined VEGF level lower than the VEGF cut-off value/range, or a determined bl-CMT level lower than the bl-CMT cut off value/range indicates that the eye has a poor anatomical response to intravitreal, suprachoroidal, and/or subretinal VEGF antagonist treatment. The aqueous humor VEGF level and/or the bl-CMT level can be used as a companion diagnostic to predict responsiveness of the subject to anti-VEGF therapies.

Abstract: A medical puncturing device and a system comprising medical apparatuses configured to be assembled into the medical puncturing device. The device or system comprises: a syringe barrel (1) comprising a distal closed end and a proximal open end; an elastic movement unit comprising an actuation member (2) and a floating seal (3) inside the syringe barrel (1), where the actuation member (2) and a floating seal (3) are capable of forming an elastic connection such that the actuation member (2) and floating seal (3) are capable of moving forward and backward relative to one another; a hollow puncture needle (6) fixedly connected to the actuation member (2) and proximal to the floating seal (3), where the hollow puncture needle (6) comprises a needle distal opening (6a) and a needle body opening (6b); and a flowable composition lumen (7) enclosed by the syringe barrel distal closed end, an inner wall of the syringe barrel, and the floating seal (3).

Abstract: A method and system for treating glaucoma can include positioning an intraocular shunt in eye tissue such that the shunt conducts fluid from the anterior chamber to a target outflow region in the eye, such as the suprachoroidal space and/or the subconjunctival space (or outside the conjunctiva).

Abstract: A medical puncturing device and a system comprising medical apparatuses configured to be assembled into the medical puncturing device. The device or system comprises: a syringe barrel (1) comprising a distal closed end and a proximal open end; an elastic movement unit comprising an actuation member (2) and a floating scal (3) inside the syringe barrel (1), where the actuation member (2) and a floating seal (3) are capable of forming an elastic connection such that the actuation member (2) and floating seal (3) are capable of moving forward and backward relative to one another; a hollow puncture needle (6) fixedly connected to the actuation member (2) and proximal to the floating seal (3), where the hollow puncture needle (6) comprises a needle distal opening (6a) and a needle body opening (6b): and a flowable composition lumen (7) enclosed by the syringe barrel distal closed end, an inner wall of the syringe barrel, and the floating seal (3).

Abstract: Disclosed are a reagent holder, a testing apparatus assembly, an aqueous humor collection device and an aqueous humor collection method. The reagent holder (9) comprises a holder body and a functional station arranged on the holder body, wherein the functional station comprises a fluid holding tube insertion hole (91) and an elastic component. The elastic component can elastically act on a fluid holding tube (106) in the case where the fluid holding tube (106) is inserted into the liquid holding tube insertion hole (91) so as to enable the fluid holding tube (106) to elastically move in the direction of the central axis of the hole of the fluid holding tube insertion hole (91).